BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625), developing its cell-based bioartificial liver system, HepaMate, as a potentially lifesaving treatment for liver failure patients, announced the appointment of four additional distinguished liver experts to its Advisory Board to further advance the company’s plans for a new clinical trial of its HepaMate bioartificial liver system and to refine the clinical strategy and patient treatment protocols.
